7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.
7-Hydroxy-MTX production after consecutive high-dose MTX therapy (12 g/m2) was measured in 7 patients with osteosarcoma by HPLC. 7-Hydroxy-MTX serum values in the last cycle were found to be significantly lower compared with the first high-dose MTX treatment of the adjuvant chemotherapy protocol (COSS 80). Moreover, in another patient highly reduced 7-hydroxy-MTX production was correlated with severe clinical toxicity. As 7-hydroxy-MTX is a 200 fold less potent dihydrofolic acid reductase inhibitor compared with MTX decreased production of the metabolite may lead to enhanced clinical toxicity which may not be predictable monitoring MTX serum levels alone.
D002851:Chromatography, High Pressure Liquid; D005493:Folic Acid Antagonists / Q000097:blood*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D012516:Osteosarcoma / Q000097:blood / Q000188:drug therapy; D013997:Time Factors
D005493:Folic Acid Antagonists; C011864:7-hydroxymethotrexate; D008727:Methotrexate